About 8 out of every 100 women diagnosed with breast cancer in the U.S. will not survive it within five years, based on the current overall five-year survival rate of 91.9%. Put another way, roughly 92% of women diagnosed today will be alive five years later. In 2026, an estimated 42,140 women will die from breast cancer out of approximately 321,910 new diagnoses. But these numbers vary dramatically depending on when the cancer is caught, its biological subtype, and the patient’s race.
Lifetime Risk of Dying From Breast Cancer
The chance of any individual woman dying from breast cancer over her entire lifetime is much lower than the number of women who get diagnosed. In high-income countries like the U.S., about 1 in 12 women will be diagnosed with breast cancer at some point, but only about 1 in 71 will ultimately die from it. That gap reflects the fact that most breast cancers are caught early and treated successfully.
In lower-income countries, the picture is different. About 1 in 27 women will be diagnosed, but 1 in 48 will die from it. Fewer diagnoses overall, yet a much higher proportion of those diagnosed don’t survive, largely because screening is less available and cancers tend to be caught at later stages.
How Stage at Diagnosis Changes Everything
The single biggest factor in whether breast cancer is fatal is how far it has spread when it’s found. Survival rates for the most common subtype of breast cancer (hormone receptor-positive, HER2-negative, which accounts for the majority of cases) illustrate this clearly:
- Localized (still in the breast): 100% five-year survival
- Regional (spread to nearby lymph nodes): 91.1% five-year survival
- Distant (metastatic, spread to other organs): 38.1% five-year survival
When breast cancer is caught before it leaves the breast, it is essentially not fatal in statistical terms. Once it reaches distant organs like the lungs, liver, bones, or brain, the odds shift substantially. This is why screening matters so much: catching cancer at a localized stage versus a distant stage can mean the difference between a near-certain survival and roughly a 1-in-3 chance.
Survival Rates by Cancer Subtype
Not all breast cancers behave the same way. Doctors classify them by whether the tumor responds to hormones and whether it produces a protein called HER2. These biological differences significantly affect how aggressive the cancer is and how well it responds to treatment.
Five-year survival rates by subtype:
- Hormone receptor-positive, HER2-negative: 95.8%. This is the most common type and the most treatable.
- Hormone receptor-positive, HER2-positive: 92.2%. Targeted therapies for HER2 have dramatically improved outcomes for this group.
- Hormone receptor-negative, HER2-positive: 87.0%. Still responds well to HER2-targeted treatments.
- Triple-negative (hormone receptor-negative, HER2-negative): 78.7%. This subtype has fewer targeted treatment options and tends to be more aggressive.
The gap widens further when you look at metastatic disease. A woman with distant-stage triple-negative breast cancer has a five-year survival rate of just 14.9%, compared to 48.7% for hormone receptor-positive, HER2-positive cancers that have also spread to distant organs. Triple-negative breast cancer accounts for a disproportionate share of breast cancer deaths relative to how common it is.
Racial Disparities in Breast Cancer Deaths
Black women in the U.S. die from breast cancer at significantly higher rates than white women. CDC data found that Black women had a 41% higher mortality rate: 31.6 deaths per 100,000 compared to 22.4 per 100,000 for white women. For every 100 breast cancers diagnosed, 27 Black women died compared to 18 white women.
Several factors drive this disparity. Black women are more likely to be diagnosed with triple-negative breast cancer, the most aggressive subtype. They also tend to be diagnosed at later stages and face barriers to timely, high-quality treatment, including gaps in insurance coverage and access to specialized cancer centers. The result is a measurable survival gap that persists even when comparing women diagnosed at the same stage.
How Death Rates Have Changed Over Time
Breast cancer mortality has dropped substantially over the past few decades. Between 1989 and 2017, the death rate fell by 40%, according to the American Cancer Society. That decline translates to hundreds of thousands of lives saved and reflects improvements on multiple fronts: mammography catching cancers earlier, more effective chemotherapy and hormonal therapies, and the development of targeted drugs for HER2-positive cancers.
The steepest drops came in the 1990s and 2000s as these advances rolled out broadly. Progress has continued since, though the pace has slowed somewhat. And the benefits haven’t been shared equally. The mortality gap between Black and white women actually widened during parts of this period, as white women benefited more from advances in early detection and treatment access.
What These Numbers Mean in Practice
If you’re looking at breast cancer statistics for the first time, the key takeaway is that the vast majority of women diagnosed with breast cancer today will survive it. A 91.9% overall five-year survival rate is among the highest for any cancer. But “breast cancer” is not a single disease. A small, localized, hormone-responsive tumor caught on a routine mammogram carries an almost entirely different prognosis than a triple-negative cancer that has already spread to other organs.
Stage at diagnosis remains the most controllable factor. Women whose cancers are found while still localized have survival rates approaching 100% regardless of subtype. Even the most aggressive subtypes have localized survival rates above 92%. The cancers that kill are overwhelmingly those that aren’t caught until they’ve spread, which reinforces the value of regular screening, particularly for women with higher baseline risk due to family history, genetics, or demographic factors that correlate with more aggressive disease.